SCHEMBL15979698

SCHEMBL15979698

Cc1csc(C(=O)CCC(=O)c2cc(Br)cs2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 3/20 0.62
DAO P14920 1/20 0.53
CES2 O00748 1/20 0.52
CES1 P23141 1/20 0.52
ALDH1A1 P00352 5/20 0.49
LMNA P02545 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.41
MEN1 O00255 2/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
KMT2A Q03164 2/20 0.38
POLB P06746 1/20 0.36
MAPT P10636 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
MAPK1 P28482 1/20 0.35
CASP1 P29466 1/20 0.35
CASP7 P55210 1/20 0.35
HSD17B10 Q99714 1/20 0.35
HRH3 Q9Y5N1 2/20 0.35
ALAD P13716 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15979699 0.91 DAO (0.63) GSK3BDAOCES2CES1ALDH1A1
SCHEMBL15988671 0.89 GSK3B (0.70) GSK3BDAOCES2CES1ALDH1A1
SCHEMBL3867877 0.84 DAO (0.55) GSK3BDAOALDH1A1LMNASMN1; SMN2
SCHEMBL6917802 0.84 DAO (0.60) GSK3BDAOALDH1A1LMNAMEN1
SCHEMBL28474265 0.81 DAO (0.57) GSK3BDAOALDH1A1LMNASMN1; SMN2
SCHEMBL15979708 0.81 DAO (0.52) GSK3BDAOALDH1A1LMNAMEN1
SCHEMBL2773258 0.80 DAO (0.55) GSK3BDAOMAPTNPSR1CASP3
SCHEMBL15547606 0.79 DAO (0.59) GSK3BDAOCES2CES1ALDH1A1
SCHEMBL23300700 0.79 GSK3B (0.54) GSK3BCES2CES1ALDH1A1LMNA
SCHEMBL5313265 0.78 DAO (0.49) GSK3BDAOCES2CES1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11673885-B2 γ-diketones as Wnt/β-catenin signaling pathway activators BIOSPLICE THERAPEUTICS, INC. (US) 2023-06-13 US disclosed
US-20180193244-A1 GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES VICKERS VENTURE FUND VI PTE. LTD. (SG) 2018-07-12 US disclosed
US-9951053-B2 γ-diketones as Wnt/β-catenin signaling pathway activators SAMUMED, LLC (US) 2018-04-24 US disclosed
US-20170260176-A1 GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS MED-PATHWAYS II LIMITED (VG) 2017-09-14 US disclosed
US-9533976-B2 γ-diketones as WNT/β-catenin signaling pathway activators SAMUMED, LLC (US) 2017-01-03 US disclosed
US-20140243349-A1 GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS VICKERS VENTURE FUND VI PTE. LTD. (SG) 2014-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180193244-A1 GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES GLA, DGKG, DGKA GSK3B 613/4885DAO 239/4885CES2 4435/4885
US-20170260176-A1 GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS GSK3A, GSK3B, WNT1 GSK3B 2/4885DAO 3651/4885CES2 4753/4885
US-20140243349-A1 GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS GSK3A, GSK3B, WNT1 GSK3B 2/4885DAO 3651/4885CES2 4753/4885
US-11673885-B2 γ-diketones as Wnt/β-catenin signaling pathway activators GSK3A, GSK3B, WNT1 GSK3B 2/4885DAO 3757/4885CES2 4749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.